Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Don't bet against Vertex Pharmaceuticals in cystic fibrosis.
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been the dominant player in the cystic fibrosis (CF) drug market, thanks to its successful medicines. This situation has led to a virtual monopoly for the company, resulting in strong performance over the years. However, some critics argue that Vertex's revenue would dwindle once competition enters the picture.
While this concern was prevalent, Sionna Therapeutics (NASDAQ: SION) appeared to be developing a potentially superior CF drug, which might have threatened Vertex's lead. Yet, recent developments suggest that Vertex may not be facing imminent competition in its core market. Here are the key points that investors need to be aware of.
To understand CF, one must first know that it is caused by mutations in the CFTR gene, leading to a defective CFTR protein. Vertex's medicines can significantly improve CFTR function, although patients rarely achieve normal protein function with these drugs. Sionna Therapeutics aims to change this by stabilizing CFTR function in most patients, as per the company's claims. However, Sionna recently faced a setback.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.